If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Mario Santinami is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 15 Similar Profiles
Melanoma Medicine & Life Sciences
Perfusion Medicine & Life Sciences
Extremities Medicine & Life Sciences
Neoplasm Metastasis Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Skin Medicine & Life Sciences
Survival Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1983 2019

  • 8296 Citations
  • 44 h-Index
  • 148 Article
  • 1 Comment/debate
  • 1 Letter
3 Citations (Scopus)

An actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells

Perotti, V., Baldassari, P., Molla, A., Nicolini, G., Bersani, I., Grazia, G., Benigni, F., Maurichi, A., Santinami, M., Anichini, A. & Mortarini, R., May 30 2019, In : Oncogene. 38, 22, p. 4384-4396 13 p.

Research output: Contribution to journalArticle

Open Access
Melanoma
Down-Regulation
Pharmacology
Phenotype
Cell Line
Open Access
Oncogenes
Actins
Melanoma
Emotions
3 Citations (Scopus)

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial

Schadendorf, D., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Lesimple, T., Plummer, R., Schachter, J., Dasgupta, K., Manson, S., Koruth, R., Mookerjee, B., Kefford, R. & 3 others, Dummer, R., Kirkwood, J. M. & Long, G. V., May 2019, In : The Lancet Oncology. 20, 5, p. 701-710 10 p.

Research output: Contribution to journalArticle

Melanoma
Placebos
Mutation
Recurrence
Quality of Life

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma

Hauschild, A., Dummer, R., Schadendorf, D., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Schachter, J., Lesimple, T., Plummer, R., Dasgupta, K., Haas, T., Shilkrut, M., Gasal, E. & 3 others, Kefford, R., Kirkwood, J. M. & Long, G. V., Oct 22 2018, In : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. p. JCO1801219

Research output: Contribution to journalArticle

Melanoma
Recurrence
Survival
Placebos
Neoplasm Metastasis

Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600–mutant stage III melanoma

Hauschild, A., Dummer, R., Schadendorf, D., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Schachter, J., Lesimple, T., Plummer, R., Dasgupta, K., Haas, T., Shilkrut, M., Gasal, E. & 3 others, Kefford, R., Kirkwood, J. M. & Long, G. V., 2018, In : Journal of Clinical Oncology. 36, 35, p. 3441-3449 9 p.

Research output: Contribution to journalArticle